Pre-RT cachexia strongly predicted treatment discontinuation in head and neck cancer
Treatment discontinuation was 25.0% with pre-RT cachexia versus 4.6% without, with approximately sixfold higher adjusted odds.
Tag
Worth Attention
CBCT-measured muscle loss during RT predicted survival in HPV-positive oropharyngeal cancer
Routine treatment CBCT detected skeletal muscle loss that independently tracked worse survival in 337 patients with HPV-positive oropharyngeal cancer.
Second malignancy risk reached 6.7% at 15 years after IMRT for nasopharyngeal cancer
Among long-term NPC survivors treated with IMRT, radiation-related second malignancy incidence reached 6.66% at 15 years.
ReCOG identifies major heterogeneity across pelvic re-irradiation trials
Nine prospective rectal and anal re-irradiation trials varied widely in dose, margins, cumulative-dose methods, organs at risk, and PRO reporting.
Ablative MR-guided RT achieved 95% local control in GEP-NETs
Among 20 mostly metastatic GEP-NET patients, MR-guided ablative RT achieved 95% local control with acute grade 3 toxicity in 10%.
Bone SABR preserved quality of life through one year in BONY-M
Quality of life remained stable after 30–37.5 Gy in three fractions, while symptomatic patients achieved 59% pain response at 24 weeks.
Longer palliative RT courses were associated with substantially more lymphopenia
Compared with 8 Gy in one fraction, five- and ten-fraction regimens were associated with approximately two- and threefold higher odds of lymphopenia.
Sequential hypofractionation improved locoregional control in locally advanced NSCLC
Sequential 55 Gy in 20 fractions achieved 62% three-year locoregional control, outperforming conventionally fractionated sequential chemoradiotherapy without greater toxicity.
Surgery plus adjuvant RT and definitive RT produced similar survival in advanced head and neck cancer
After propensity matching, overall survival was similar between surgery plus adjuvant RT and definitive RT, while disease-control differences remained non-significant.
Whole-heart dose concealed high cardiac substructure exposure in left-sided lung radiotherapy
Despite a mean whole-heart dose below 9 Gy, eleven cardiac substructures averaged above 10 Gy, and targeted replanning substantially reduced coronary exposure.
Tumor Y-chromosome loss was associated with a radioresistant phenotype across cancers
Loss of the Y chromosome tracked with greater cancer-cell survival after irradiation and worse outcomes in selected radiotherapy-treated male patients.
Cystic vestibular schwannomas shrank earlier after SRS than solid tumors
Large cystic Koos III–IV vestibular schwannomas showed greater early shrinkage after SRS, with 100% local control in 15 cystic cases.
SBRT timing relative to chemotherapy did not affect survival in stage I SCLC
Stage I SCLC survival was similar whether SBRT preceded chemotherapy or was delivered after chemotherapy had started.
Higher radiotherapy dose tracked with greater pathological response in neoadjuvant esophageal chemoradiotherapy
Each 10-Gy increase in biologically effective dose was associated with 39% higher odds of pathological complete response in esophageal squamous cell carcinoma.
Advanced extranodal extension improved N3 risk identification in nasopharyngeal carcinoma
Adding advanced extranodal extension to N3 modestly improved prognostic discrimination and identified patients with substantially greater distant failure risk.